Amonafide + ara-C in secondary acute myeloid leukemia (sAML): Consistent efficacy in poor risk populations

Authors :: Ante Sven Lundberg
Bayard L. Powell
Robert L. Capizzi
M R O'Donnell
David A. Rizzieri
John M. Bennett
Harry P. Erba
Source :: Journal of Clinical Oncology. 26:7027-7027
Publication Year :: 2008
Publisher :: American Society of Clinical Oncology (ASCO), 2008.
Abstract: 7027 Background: The poor prognosis for sAML (prior MDS or leukemogenic therapy, i.e., tAML) relates to disease (unfavorable cytogenetics and multidrug resistance (MDR) phenotype) and patient (pt) ...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Poor risk
business.industry
Cytogenetics
Amonafide
Disease
Phenotype
Leukemogenic
Multiple drug resistance
Internal medicine
medicine
Secondary Acute Myeloid Leukemia
business

Tools